Association of Mitochondrial Pyruvate Carrier with the Clinical and Histological Features in Lupus Nephritis

References

• Anders H-J, Saxena R, Zhao M-H, Parodis I, Salmon JE, Mohan C. Lupus nephritis. Nat Rev Dis Primers. 2020;6(1):7. doi:10.1038/s41572-019-0141-9
   PubMed Web of Science ®Google Scholar
• Kwon OC, Park JH, Park H-C, et al. Non-histologic factors discriminating proliferative lupus nephritis from membranous lupus nephritis. Arthritis Res Ther. 2020;22(1):138. doi:10.1186/s13075-020-02223-x
   PubMed Web of Science ®Google Scholar
• Zuo Z, Jing K, Wu H, et al. Mechanisms and Functions of Mitophagy and Potential Roles in Renal Disease. Front Physiol. 2020;11:935. doi:10.3389/fphys.2020.00935
   PubMed Web of Science ®Google Scholar
• Ward MM. Prevalence of physician-diagnosed systemic lupus erythematosus in the United States: results from the third national health and nutrition examination survey. J Womens Health. 2004;13(6):713–718. doi:10.1089/jwh.2004.13.713
   Web of Science ®Google Scholar
• Maroz N, Segal MS. Lupus nephritis and end-stage kidney disease. Am J Med Sci. 2013;346(4):319–323. doi:10.1097/MAJ.0b013e31827f4ee3
   PubMed Web of Science ®Google Scholar
• Ding H, Lin C, Cai J, et al. Urinary activated leukocyte cell adhesion molecule as a novel biomarker of lupus nephritis histology. Arthritis Res Ther. 2020;22(1):122. doi:10.1186/s13075-020-02209-9
   PubMed Web of Science ®Google Scholar
• Tavoulari S, Thangaratnarajah C, Mavridou V, Harbour ME, Martinou J-C, Kunji ER. The yeast mitochondrial pyruvate carrier is a hetero-dimer in its functional state. EMBO J. 2019;38(10). doi:10.15252/embj.2018100785
   PubMed Web of Science ®Google Scholar
• Yang S-K, Zhang H-R, Shi S-P, et al. The Role of Mitochondria in Systemic Lupus Erythematosus: a Glimpse of Various Pathogenetic Mechanisms. Curr Med Chem. 2020;27(20):3346–3361. doi:10.2174/0929867326666181126165139
   PubMed Web of Science ®Google Scholar
• Gergely P, Grossman C, Niland B, et al. Mitochondrial hyperpolarization and ATP depletion in patients with systemic lupus erythematosus. Arthritis Rheum. 2002;46(1):175–190. doi:10.1002/1529-0131(200201)46:1<175::AID-ART10015>3.0.CO;2-H
   PubMed Web of Science ®Google Scholar
• López-López L, Nieves-Plaza M, Castro M, et al. Mitochondrial DNA damage is associated with damage accrual and disease duration in patients with systemic lupus erythematosus. Lupus. 2014;23(11):1133–1141. doi:10.1177/0961203314537697
   PubMed Web of Science ®Google Scholar
• Gray LR, Tompkins SC, Taylor EB. Regulation of pyruvate metabolism and human disease. Cell Mol Life Sci. 2014;71(14):2577–2604. doi:10.1007/s00018-013-1539-2
   PubMed Web of Science ®Google Scholar
• Li X, Ji Y, Han G, et al. MPC1 and MPC2 expressions are associated with favorable clinical outcomes in prostate cancer. BMC Cancer. 2016;16(1):894. doi:10.1186/s12885-016-2941-6
   PubMedGoogle Scholar
• Tauffenberger A, Fiumelli H, Almustafa S, Magistretti PJ. Lactate and pyruvate promote oxidative stress resistance through hormetic ROS signaling. Cell Death Dis. 2019;10(9):653. doi:10.1038/s41419-019-1877-6
   PubMedGoogle Scholar
• Feng J, Ma Y, Chen Z, Hu J, Yang Q, Ding G. Mitochondrial pyruvate carrier 2 mediates mitochondrial dysfunction and apoptosis in high glucose-treated podocytes. Life Sci. 2019;237:116941. doi:10.1016/j.lfs.2019.116941
   PubMed Web of Science ®Google Scholar
• Zhu H, Wan H, Wu L, et al. Mitochondrial pyruvate carrier: a potential target for diabetic nephropathy. BMC Nephrol. 2020;21(1):274. doi:10.1186/s12882-020-01931-5
   PubMed Web of Science ®Google Scholar
• Herzig S, Raemy E, Montessuit S, et al. Identification and functional expression of the mitochondrial pyruvate carrier. Science. 2012;337(6090):93–96. doi:10.1126/science.1218530
   PubMed Web of Science ®Google Scholar
• Zhu H, Wan H, Wu L, et al. Mitochondrial pyruvate carrier: a potential target for diabetic nephropathy. BMC Nephrol. 2020;21(1):274.
   PubMed Web of Science ®Google Scholar
• Petri M, Orbai A-M, Alarcón GS, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64(8):2677–2686. doi:10.1002/art.34473
   PubMed Web of Science ®Google Scholar
• Hahn BH, McMahon MA, Wilkinson A, et al. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res. 2012;64(6):797–808. doi:10.1002/acr.21664
   PubMed Web of Science ®Google Scholar
• Weening JJ, D’Agati VD, Schwartz MM, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int. 2004;65(2):521–530. doi:10.1111/j.1523-1755.2004.00443.x
   PubMed Web of Science ®Google Scholar
• Bajema IM, Wilhelmus S, Alpers CE, et al. Revision of the International Society of Nephrology/Renal Pathology Society classification for lupus nephritis: clarification of definitions, and modified National Institutes of Health activity and chronicity indices. Kidney Int. 2018;93(4):789–796. doi:10.1016/j.kint.2017.11.023
   PubMed Web of Science ®Google Scholar
• Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604–612. doi:10.7326/0003-4819-150-9-200905050-00006
   PubMed Web of Science ®Google Scholar
• Soliman S, Mohamed FA, Ismail FM, Stanley S, Saxena R, Mohan C. Urine angiostatin and VCAM-1 surpass conventional metrics in predicting elevated renal pathology activity indices in lupus nephritis. Int J Rheum Dis. 2017;20(11):1714–1727. doi:10.1111/1756-185X.13197
   PubMed Web of Science ®Google Scholar
• Nozaki Y, Kinoshita K, Yano T, et al. Estimation of kidney injury molecule-1 (Kim-1) in patients with lupus nephritis. Lupus. 2014;23(8):769–777. doi:10.1177/0961203314526292
   PubMed Web of Science ®Google Scholar
• Bethunaickan R, Berthier CC, Zhang W, et al. Identification of stage-specific genes associated with lupus nephritis and response to remission induction in (NZB × NZW)F1 and NZM2410 mice. Arthritis Rheumatol. 2014;66(8):2246–2258. doi:10.1002/art.38679
   PubMed Web of Science ®Google Scholar
• Davidson A. What is damaging the kidney in lupus nephritis? Nat Rev Rheumatol. 2016;12(3):143–153. doi:10.1038/nrrheum.2015.159
   PubMed Web of Science ®Google Scholar
• Yang S, Han Y, Liu J, et al. Mitochondria: a Novel Therapeutic Target in Diabetic Nephropathy. Curr Med Chem. 2017;24(29):3185–3202. doi:10.2174/0929867324666170509121003
   PubMed Web of Science ®Google Scholar
• Bhargava P, Schnellmann RG. Mitochondrial energetics in the kidney. Nat Rev Nephrol. 2017;13(10):629–646. doi:10.1038/nrneph.2017.107
   PubMed Web of Science ®Google Scholar
• Aparicio-Trejo OE, Tapia E, Sánchez-Lozada LG, Pedraza-Chaverri J. Mitochondrial bioenergetics, redox state, dynamics and turnover alterations in renal mass reduction models of chronic kidney diseases and their possible implications in the progression of this illness. Pharmacol Res. 2018;135.
   Web of Science ®Google Scholar
• Han P, Weng W, Chen Y, et al. Niclosamide ethanolamine attenuates systemic lupus erythematosus and lupus nephritis in MRL/lpr mice. Am J Transl Res. 2020;12(9):5015–5031.
   PubMed Web of Science ®Google Scholar
• Sampson AL, Singer RF, Walters GD. Uric acid lowering therapies for preventing or delaying the progression of chronic kidney disease. Cochrane Database Syst Rev. 2017;10:CD009460.
   PubMedGoogle Scholar
• Moroni G, Vercelloni PG, Quaglini S, et al. Changing patterns in clinical-histological presentation and renal outcome over the last five decades in a cohort of 499 patients with lupus nephritis. Ann Rheum Dis. 2018;77(9):1318–1325. doi:10.1136/annrheumdis-2017-212732
   PubMed Web of Science ®Google Scholar
• Ichinose K, Kitamura M, Sato S, et al. Factors predictive of long-term mortality in lupus nephritis: a multicenter retrospective study of a Japanese cohort. Lupus. 2019;28(3):295–303. doi:10.1177/0961203319826690
   PubMed Web of Science ®Google Scholar